Latest & greatest articles for statin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on statin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on statin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for statin

181. Depression 3 and 9 months after discharge is less common in cardiac patients who are receiving statins at discharge

Depression 3 and 9 months after discharge is less common in cardiac patients who are receiving statins at discharge Depression 3 and 9 months after discharge is less common in cardiac patients who are receiving statins at discharge | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Depression 3 and 9 months after discharge is less common in cardiac patients who are receiving statins at discharge Article Text Prognosis Depression 3

2012 Evidence-Based Mental Health

182. Statin use and risk of prostate cancer: a meta-analysis of observational studies

Statin use and risk of prostate cancer: a meta-analysis of observational studies Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

183. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Full Text available with Trip Pro

Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. In view of evidence that statin therapy increases risk of diabetes, the balance of benefit and risk of these drugs in primary prevention has become controversial. We undertook an analysis of participants from the JUPITER trial to address the balance of vascular benefits and diabetes hazard of statin use.In the randomised, double-blind JUPITER trial, 17,603 men and women (...) none or at least one of four major risk factors for developing diabetes: metabolic syndrome, impaired fasting glucose, body-mass index 30 kg/m(2) or higher, or glycated haemoglobin A(1c) greater than 6%. The trial is registered at ClinicalTrials.gov, NCT00239681.Trial participants with one or more major diabetes risk factor (n=11,508) were at higher risk of developing diabetes than were those without a major risk factor (n=6095). In individuals with one or more risk factors, statin allocation

2012 Lancet Controlled trial quality: predicted high

184. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlle (Abstract)

Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlle Inhibition of proprotein convertase subtilisin/kexin type 9 serine protease (PCSK9) resulted in large reductions of low-density lipoprotein cholesterol (LDL-C) in phase 1 trials. We assessed the efficacy and safety of various doses and dosing (...) intervals of REGN727, a monoclonal antibody to PCSK9, added to statins, to further lower LDL-C in patients with heterozygous familial hypercholesterolaemia.This multicentre, randomised, placebo-controlled phase 2 trial was done at 16 lipid clinics in the USA and Canada. Between Jan 18, 2011, and Nov 7, 2011, we enrolled adults with heterozygous familial hypercholesterolaemia and LDL-C concentrations of 2·6 mmol/L or higher on stable diet and statin dose, with or without ezetimibe. Patients were randomly

2012 Lancet Controlled trial quality: predicted high

185. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. Full Text available with Trip Pro

Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. An estimated 10% to 20% of patients cannot tolerate statins or adequate doses to achieve treatment goals. Plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to low-density lipoprotein (LDL) receptors, promoting their degradation and increasing LDL cholesterol levels. In phase 1 studies, a human monoclonal antibody to PCSK9, AMG145 (...) , was well tolerated and reduced LDL cholesterol levels.To assess the efficacy and tolerability of AMG145 in patients with statin intolerance due to muscle-related side effects.A 12-week, randomized, double-blind, placebo- and ezetimibe-controlled, dose-ranging study conducted between July 2011 and May 2012 in statin-intolerant adult patients at 33 international sites.Patients were randomized equally to 1 of 5 groups: AMG145 alone at doses of 280 mg, 350 mg, or 420 mg; AMG145 at 420 mg plus 10 mg

2012 JAMA Controlled trial quality: predicted high

186. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 stu Full Text available with Trip Pro

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 stu LDL cholesterol (LDL-C) is a well established risk factor for cardiovascular disease. Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds LDL receptors, targeting them for degradation. We therefore assessed the efficacy, safety (...) , and tolerability of AMG 145, a human monoclonal IgG2 antibody against PCSK9, in stable patients with hypercholesterolemia on a statin.In a phase 2, dose-ranging study done in 78 centres in the USA, Canada, Denmark, Hungary, and Czech Republic, patients (aged 18-80 years) with LDL-C greater than 2·2 mmol/L on a stable dose of statin (with or without ezetimibe), were randomly assigned equally, through an interactive voice response system, to subcutaneous injections of AMG 145 70 mg, 105 mg, or 140 mg

2012 Lancet Controlled trial quality: uncertain

187. Systematic review and meta-analysis: High-dose statin before percutaneous coronary intervention lowers risk of periprocedural myocardial infarction and 30-day major cardiac adverse events

Systematic review and meta-analysis: High-dose statin before percutaneous coronary intervention lowers risk of periprocedural myocardial infarction and 30-day major cardiac adverse events High-dose statin before percutaneous coronary intervention lowers risk of periprocedural myocardial infarction and 30-day major cardiac adverse events | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via (...) your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here High-dose statin before percutaneous coronary

2012 Evidence-Based Medicine

188. Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis

Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

189. Statins and prevention of infections: systematic review and meta-analysis of data from large randomised placebo controlled trials

Statins and prevention of infections: systematic review and meta-analysis of data from large randomised placebo controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

190. Statins for primary prevention of venous thromboembolism. (Abstract)

Statins for primary prevention of venous thromboembolism. Venous thromboembolism (VTE) is common in clinical practice. The efficacy of statins in the primary prevention of VTE remains unproven.To assess the efficacy of statins in the primary prevention of VTE.The Cochrane Peripheral Vascular Diseases (PVD) Group searched their Specialised Register (last searched April 2011) and CENTRAL (2011, Issue 2). The authors searched MEDLINE (January 1966 to March 2011); EMBASE (1974 to March 2011); ISI (...) Web of Knowledge (2001 to March 2011); the Chinese Biomedical Literature Database (1978 to March 2011) and other resources (including clinical trials registers, reference lists and presentations at various conferences.Randomised controlled trials (RCTs) that assessed statins were considered. The outcomes we evaluated were the rates of VTE, cardiovascular and cerebrovascular events, death and adverse events. Two authors independently selected RCTs against inclusion criteria. Disagreements were

2011 Cochrane

191. Effects of statin treatment on cardiac function in patients with chronic heart failure: a meta-analysis of randomized controlled trials

Effects of statin treatment on cardiac function in patients with chronic heart failure: a meta-analysis of randomized controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 DARE.

192. Cost-effectiveness of the use of low- and high-potency statins in people at low cardiovascular risk Full Text available with Trip Pro

Cost-effectiveness of the use of low- and high-potency statins in people at low cardiovascular risk Although statins have been shown to reduce the risk of cardiovascular events in patients at low cardiovascular risk, their absolute benefit is small in the short term, which may adversely affect cost-effectiveness. We sought to determine the long-term cost-effectiveness (beyond the duration of clinical trials) of low- and high-potency statins in patients at low cardiovascular risk and to estimate (...) the impact on Canada's publicly funded health care system.Using Markov modelling, we performed a cost-utility analysis in which we compared low-potency statins (fluvastatin, lovastatin, pravastatin and simvastatin) and high-potency statins (atorvastatin and rosuvastatin) with no statins in a simulated cohort of low-risk patients over a lifetime horizon. Model outcomes included costs (in 2010 Canadian dollars), quality-adjusted life-years (QALYs) gained and the cost per QALY gained.Over a lifetime horizon

2011 EvidenceUpdates

193. Needed: Pragmatic Clinical Trials for Statin-Intolerant Patients. Full Text available with Trip Pro

Needed: Pragmatic Clinical Trials for Statin-Intolerant Patients. 22085320 2011 12 22 2015 11 19 1533-4406 365 24 2011 Dec 15 The New England journal of medicine N. Engl. J. Med. Needed: pragmatic clinical trials for statin-intolerant patients. 2250-1 10.1056/NEJMp1112023 Maningat Patricia P Rockefeller University, New York, USA. Breslow Jan L JL eng Journal Article 2011 11 15 United States N Engl J Med 0255562 0028-4793 0 Hydroxymethylglutaryl-CoA Reductase Inhibitors 0 Hypolipidemic Agents (...) 2679MF687A Niacin EC 2.7.3.2 Creatine Kinase AIM IM Clinical Trials as Topic Creatine Kinase blood Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors adverse effects Hypercholesterolemia drug therapy Hypolipidemic Agents adverse effects therapeutic use Medication Adherence Muscular Diseases chemically induced diagnosis Niacin therapeutic use 2011 11 17 6 0 2011 11 17 6 0 2011 12 23 6 0 ppublish 22085320 10.1056/NEJMp1112023

2011 NEJM

194. Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis Full Text available with Trip Pro

from the Netherlands Organisation for Health Research and Development (ZonMW). Bibliographic details Greving JP, Visseren FL, de Wit GA, Algra A. Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis. BMJ 2011; 342:d1672 PubMedID DOI Original Paper URL Indexing Status Subject indexing assigned by NLM MeSH Aged; Cost-Benefit Analysis; Female; Fluorobenzenes /therapeutic use; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors /economics (...) Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis Greving JP, Visseren FL, de Wit GA, Algra A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains

2011 NHS Economic Evaluation Database.

195. Arterial endothelial function and wall thickness in familial hypercholesterolemia and familial combined hyperlipidemia and the effect of statins: a systematic review and meta-analysis

Arterial endothelial function and wall thickness in familial hypercholesterolemia and familial combined hyperlipidemia and the effect of statins: a systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 DARE.

196. Statins for Acute Coronary Syndrome

Statins for Acute Coronary Syndrome Statins for Acute Coronary Syndrome – TheNNTTheNNT Statins for Acute Coronary Syndrome No benefit found In Summary, for those who took the statins (within 14 days of MI): Benefits in NNT 100% saw no benefit None were helped by preventing death, heart attack, stroke, or heart failure None were helped (life saved; heart attack, stroke, or heart failure prevented) Harms in NNT An unknown number were harmed by medication side effects/adverse reactions An unknown (...) number were harmed (medication side effects/adverse reactions) View As: NNT % Source: Efficacy Endpoints: Death, heart attack, stroke, acute heart failure, unstable angina Harm Endpoints: Myopathy, rhabdomyolysis Narrative: Patients are at highest risk of severe adverse events in the early period after an episode of acute coronary syndrome (ACS). Beyond their cholesterol lowering properties, some experimental data suggests that statins may improve endothelial function, decrease platelet aggregation

2011 theNNT

197. Systematic review and meta-analysis of the effects of statin therapy on abdominal aortic aneurysms

Systematic review and meta-analysis of the effects of statin therapy on abdominal aortic aneurysms Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 DARE.

198. Usefulness of statins pretreatment for the prevention of postoperative atrial fibrillation in patients undergoing cardiac surgery

Usefulness of statins pretreatment for the prevention of postoperative atrial fibrillation in patients undergoing cardiac surgery Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 DARE.

199. Comparative effectiveness of rosuvastatin versus other statins: a review of clinical effectiveness

similar effects on HDL, TG and CRP with rosuvastatin compared with other statins. Based on the identified literature, there is no significant difference in rates of adverse events between rosuvastatin and other statins. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Fluorobenzeness; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Sulfonamides Language Published English Country of organisation Canada Province or state Ontario Address for correspondence Canadian (...) Comparative effectiveness of rosuvastatin versus other statins: a review of clinical effectiveness Comparative effectiveness of rosuvastatin versus other statins: a review of clinical effectiveness Comparative effectiveness of rosuvastatin versus other statins: a review of clinical effectiveness Canadian Agency for Drugs and Technologies in Health Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality

2011 Health Technology Assessment (HTA) Database.

200. Red Yeast Rice: Nature?s Statin?

. American spending on RYR increased nearly .[2] To synthesize RYR, red yeast is cultured on white rice and then fermented. The yeast is subsequently inactivated and the rice-yeast product is converted to a powder. Chemical analysis reveals that RYR contains 10 different types of monacolins, which are known as 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitors. A particularly interesting component of RYR is monacolin K, which is chemically identical to lovastatin and has been shown (...) between treatment and control groups. The study’s authors suggest that other compounds in RYR besides monacolin K may also inhibit HMG-CoA reductase. These same compounds may also be less likely to deplete mevalonate metabolites distal to HMG-CoA reductase that are believed to mediate statin-induced muscle injury, such as guanosine triphosphate-binding regulatory proteins and intracellular isoprenoids, including ubiquinone. The Becker study has two notable shortcomings. First, the median time

2011 Clinical Correlations